{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Disorders&page=2",
    "query": {
      "condition": "Myotonic Disorders",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myotonic+Disorders&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T21:57:56.898Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05004129",
      "title": "Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Myotonic Dystrophy"
      ],
      "interventions": [
        {
          "name": "Tideglusib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AMO Pharma Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "6 Years to 45 Years"
      },
      "enrollment_count": 76,
      "start_date": "2021-08-23",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-05-28",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 10,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05004129"
    },
    {
      "nct_id": "NCT06411288",
      "title": "Global Study of Del-desiran for the Treatment of DM1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "DM1",
        "Myotonic Dystrophy",
        "Myotonic Dystrophy 1",
        "Myotonia",
        "Myotonic Dystrophy Type 1 (DM1)",
        "Dystrophy Myotonic",
        "Myotonic Disorders",
        "Steinert Disease",
        "Steinert",
        "Myotonic Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "AOC 1001 (del-desiran)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 159,
      "start_date": "2024-05-30",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 18,
      "location_summary": "Stanford, California • Denver, Colorado • Gainesville, Florida + 15 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06411288"
    },
    {
      "nct_id": "NCT02312011",
      "title": "A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy Type 1"
      ],
      "interventions": [
        {
          "name": "IONIS-DMPKRx",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "20 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2014-12",
      "completion_date": "2016-08",
      "has_results": false,
      "last_update_posted_date": "2022-12-06",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 8,
      "location_summary": "Stanford, California • Gainesville, Florida • Kansas City, Kansas + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02312011"
    },
    {
      "nct_id": "NCT07608432",
      "title": "Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy (DMD)",
        "Muscular Dystrophy, Duchenne",
        "Muscular Dystrophy (DMD)",
        "DMD",
        "Muscular Dystrophies",
        "Muscular Dystrophy in Children",
        "Muscular Dystrophy, Duchenne Type",
        "Muscular Dystrophy, Duchenne and Becker Types",
        "Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)",
        "Genetic Disease, Inborn",
        "Genetic Disease, X-Linked",
        "Congenital, Hereditary, and Neonatal Diseases and Abnormalities",
        "Neuromuscular Diseases (NMD)"
      ],
      "interventions": [
        {
          "name": "Zeleciment Rostudirsen (DYNE-251)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dyne Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "18 Years",
        "sex": "MALE",
        "summary": "4 Years to 18 Years · Male only"
      },
      "enrollment_count": 90,
      "start_date": "2026-06",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 1,
      "location_summary": "Hillsborough, North Carolina",
      "locations": [
        {
          "city": "Hillsborough",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07608432"
    },
    {
      "nct_id": "NCT03959189",
      "title": "Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myotonic Dystrophy, Type 1 (DM1)",
        "Myotonic Dystrophy"
      ],
      "interventions": [
        {
          "name": "ERX-963",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Expansion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2019-06-17",
      "completion_date": "2020-04-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-23",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Miami, Florida • Iowa City, Iowa + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Chevy Chase",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03959189"
    },
    {
      "nct_id": "NCT02308657",
      "title": "Multicenter Observational Study of Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Myotonic Dystrophy Type 1"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2013-11",
      "completion_date": "2017-10",
      "has_results": false,
      "last_update_posted_date": "2017-10-26",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Gainesville, Florida • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02308657"
    },
    {
      "nct_id": "NCT00244413",
      "title": "Characteristics of Nondystrophic Myotonias",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nondystrophic Myotonias",
        "Myotonia Congenita",
        "Myotonic Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Richard Barohn, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 94,
      "start_date": "2006-02",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2013-03-06",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 4,
      "location_summary": "Kansas City, Kansas • Boston, Massachusetts • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244413"
    },
    {
      "nct_id": "NCT05027269",
      "title": "Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "DM1",
        "Myotonic Dystrophy 1",
        "Myotonic Dystrophy",
        "Myotonic Dystrophy Type 1 (DM1)",
        "Dystrophy Myotonic",
        "Myotonic Disorders",
        "Steinert Disease",
        "Myotonic Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "AOC 1001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avidity Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 39,
      "start_date": "2021-10-28",
      "completion_date": "2023-02-14",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05027269"
    },
    {
      "nct_id": "NCT05224778",
      "title": "DMCRN-02-001: Assessing Pediatric Endpoints in DM1",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Congenital Myotonic Dystrophy",
        "CDM"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "59 Months",
        "sex": "ALL",
        "summary": "Up to 59 Months"
      },
      "enrollment_count": 50,
      "start_date": "2022-08-24",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Fairway, Kansas • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05224778"
    },
    {
      "nct_id": "NCT00577577",
      "title": "Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myotonic Dystrophy Type 1"
      ],
      "interventions": [
        {
          "name": "rhIGF-I/rhIGFBP-3",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 69,
      "start_date": "2007-12",
      "completion_date": "2008-12-29",
      "has_results": true,
      "last_update_posted_date": "2022-01-06",
      "last_synced_at": "2026-07-22T21:57:56.898Z",
      "location_count": 12,
      "location_summary": "Orange, California • Sacramento, California • Kansas City, Kansas + 9 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00577577"
    }
  ]
}